Late-onset hypogonadism in men: Uncertain disease entity and reservations regarding treatment with testosterone;Laat hypogonadisme ('late-onset hypogonadism') bij mannen: Onzekere ziekte-entiteit en reserves bij de behandeling met testosteron

Nederlands Tijdschrift voor Geneeskunde

Volumn 150, Issue 35, 2006, Pages 1925-1928

  Nieuwenhuijzen Kruseman, A C ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

BODY COMPOSITION; DRUG SAFETY; HUMAN; HYPOGONADISM; MALE; PROSTATE CANCER; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR;

AGE OF ONSET; BODY COMPOSITION; HUMANS; HYPOGONADISM; MALE; SAFETY; TESTOSTERONE; TREATMENT OUTCOME;

EID: 33749251629     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Morales A. Andropause (or symptomatic late-onset hypogonadism): facts, fiction and controversies. Aging Male. 2004;7:297-303.
2. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26:833-76.
3. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl. 2005;28:125-7.
4. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724-31.
5. Keenan DM, Veldhuis JD. Disruption of the hypothalamic luteinizing hormone pulsing mechanism in aging men. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1917-24.
6. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-72.
7. Motley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49:1239-42.
8. Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf). 2000;53:703-11.
9. Heinemann LAJ. Aging males' symptoms scale: a standardized instrument for the practice. J Endocrinol Invest. 2005;28(11 Suppl Proceedings):34-8.
10. Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, et al. Testosterone replacement therapy: current trends and future directions. Hum Reprod Update. 2004;10:409-19.
11. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482-92.
12. Jockenhövel F. Testosterone therapy - what, when and to whom? Aging Male. 2004;7:319-24.
13. Liu PY, Swerdloff RS, Veldhuis JD. The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab. 2004;89:4789-96.
14. Snyder PJ. Hypogonadism in elderly men - what to do until the evidence comes. N Engl J Med. 2004;350:440-2.
15. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63:280-93.
16. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf). 2005;63:381-94.
17. Shabsigh R. Testosterone therapy in erectile dysfunction and hypogonadism. J Sex Med. 2005;2:785-92.
18. Giannoulis MG, Sonksen PH, Umpleby M, Breen L, Pentecost C, Whyte M, et al. The effects of growth hormone and/or testosterone in healthy elderly men: a randomized controlled trial. J Clin Endocrinol Metab. 2006;91:477-84.
19. Ebert T. Clinical experiences with testosterone therapy: prostate safety. Aging Male. 2004;7:304-11.
20. Gould DC, Kirby RS. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer? Prostate Cancer Prostatic Dis. 2006;9:14-8.
21. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR, Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003;24:299-311.
22. Barrett-Connor E, Bhasin S. Time for (more research on) testosterone. J Clin Endocrinol Metab. 2004;89:501-2.